Pazopanib (Viant) original research manufacturer information and official production background introduction

Pazopanib is an oral multi-target tyrosine kinase inhibitor mainly used to treat solid tumors such as advanced renal clear cell carcinoma and soft tissue sarcoma. The drug was developed by Pfizer Inc. in the United States and is one of its important targeted anti-cancer drugs. Pfizer has extensive experience in the research and development of anti-tumor targeted drugs, and pazopanib is another innovative product after sunitinib and sorafenib.

The research and development of pazopanib began in the early 2000s. Through in-depth research on the angiogenesis pathway, Pfizer identified key targets such as VEGFR, PDGFR and c-Kit and designed multi-target inhibitors. The drug has been verified in multi-center clinical trials and has shown good efficacy and safety in patients with advanced renal clear cell carcinoma and soft tissue sarcoma, providing a new option for targeted therapy.

In terms of production, Pfizer has a global production system and strictGMP (Good Manufacturing Practice) standards. The production plants of pazopanib's original drug are located in the United States and some overseas bases. They have passed certifications from drug regulatory authorities in many countries, ensuring that the quality, purity and stability of each batch of drugs meet international standards. Pfizer also strictly controls the raw material supply chain to ensure the consistency and traceability of drug ingredients.

After its launch, pazopanib was supplied to many countries and regions around the world through Pfizer’s official channels. In order to ensure that patients receive regular drugs, Pfizer has established a complete sales and logistics system, while providing clinical support and drug use guidance. Domestically, original drugs enter the market through imports and authorized sales channels, providing patients with safe and reliable treatment options, while also promoting the popularization and clinical application of targeted anti-cancer drugs.

Reference link:https://www.drugs.com